There is currently no approved cure or vaccine for Nipah virus, a deadly bat-borne virus that can be fatal in up to 75% of cases. However, promising developments, including trials of a PSI-developed vaccine candidate, are underway to combat this devastating virus.
PSI’s Nipah Virus Research Day 2025 spotlighted the breadth of research across the Institute aiming to improve the ability to respond to Nipah virus outbreaks, focusing on the translation of cutting-edge insights into new tools and bringing together researchers from across PSI and the University of Oxford, as well as external collaborators.
Keynote speaker Dr Manuela Mura from the European Medicines Agency (EMA) spoke on the pathways to vaccine licensure for emerging pathogens, and the day included updates on clinical trials of the ChAdOx1-Nipah B vaccine, developed by PSI scientists, which after undergoing its first in-human trials in Oxford received early support from the EMA this summer. The World's first Phase II trial for a Nipah virus vaccine launched in December 2025 in Bangladesh using the ChAdOx1 NipahB vaccine.
Read the full story on the Pandemic Sciences Institute website.